Aims for the study:

• To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting hepatic steatosis in chronic hepatitis B
•  To correlate LIVERFASt steatosis with Fibroscan Controlled Attenuation Parameter (CAP) scores